Updated:
SomaLogic
SomaLogic was founded in 2000 by Larry Gold, a molecular biologist who previously co-founded NeXagen (later NeXstar Pharmaceuticals).
SomaLogic
SomaLogic was founded in 2000 by Larry Gold, a molecular biologist who previously co-founded NeXagen (later NeXstar Pharmaceuticals). The company developed SomaScan, a proteomics platform that uses modified aptamers to measure over 11,000 proteins in blood, aiming to shift diagnostics toward multi-protein patterns rather than single biomarkers. Gold stepped down as CEO in 2022; Adam Taich, a former executive at Genentech and Roche, succeeded him. Strategy centers on licensing the SomaScan platform to pharmaceutical and biotech firms for drug development, clinical trial monitoring, and population-health studies. The firm derives revenue from assay services and royalties. Partnerships include a collaboration with Novo Nordisk for diabetes and cardiovascular research, and a deal with the UK Biobank to profile proteins in 300,000 participant samples (per SomaLogic, 2021). Geographical footprint covers North America and Europe, with offices in Boulder, Colorado and Basel, Switzerland. The company went public via a SPAC merger in 2021, raising $1.1 billion in gross proceeds (per SEC filing, 2021). As of 2025, market capitalization sits at approximately $350 million. No team size, AUM, or deployment data is publicly disclosed; the firm does not operate as a family office or asset manager in the traditional sense. SomaLogic's structural differentiator is its proprietary aptamer-based assay — unlike antibody-based methods, aptamers are chemically synthesized, enabling scalable, reproducible protein measurement. This positions the firm as a platform company at the intersection of diagnostics and data services, rather than a conventional diagnostics manufacturer or single-indication test developer.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boulder
Corporate office
Boulder, CO, United States
Additional offices
Basel, Switzerland
Principals
Adam Taich
Chief Executive Officer
Larry Gold
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at SomaLogic?
Adam Taich has been CEO since 2022, succeeding founder Larry Gold. The firm is a publicly traded biotechnology company, so investment decisions — such as capital allocation and R&D spending — are made by management and approved by its board of directors. No family office or wealth management structure exists.
How does SomaLogic source proprietary deal flow?
SomaLogic generates revenue through partnerships and service agreements with pharmaceutical companies, academic institutions, and biobanks. Its proprietary SomaScan platform serves as the core offering, and the firm actively pursues collaborations to integrate the assay into large-scale clinical trials and population-health studies.
Is SomaLogic structured as a single family office or does it operate more like a venture firm?
Neither. SomaLogic is a publicly traded biotechnology company (NASDAQ: SLGC) focused on proteomics. It is not a family office, asset manager, or venture capital firm. The company operates as a diagnostics and data-services platform.
Does SomaLogic participate in fund commitments or only direct deals?
SomaLogic does not participate in fund commitments or direct investments. Its business model is based on licensing and service fees from its proteomics platform. The firm is not an investment vehicle.
What investment stages does SomaLogic typically target?
SomaLogic does not target investment stages. The company's focus is on R&D and commercialization of its SomaScan assay. It engages with partners at various stages of drug development, from preclinical research to Phase III trials.
Which sectors does SomaLogic explicitly avoid?
SomaLogic's platform is broadly applicable across therapeutic areas, but publicly disclosed partnerships focus on cardiometabolic diseases, oncology, and neuroscience. No explicit sector avoidance is documented.
Where does the underlying wealth come from?
SomaLogic is a publicly traded company, not a family office or trust. Its capital comes from public equity markets, including funds raised via its SPAC merger in 2021. No individual or family wealth is managed through the entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: